Article

FDA OKs azithromycin 1% ophthalmic solution

InSite Vision Inc. expects its azithromycin 1% ophthalmic solution (Aza- Site) to be launched commercially in the United States in the second half of this year now that the FDA has approved the company's new drug application.

Alameda, CA-InSite Vision Inc. expects its azithromycin 1% ophthalmic solution (Aza- Site) to be launched commercially in the United States in the second half of this year now that the FDA has approved the company's new drug application.

The topical anti-infective, for the treatment of bacterial conjunctivitis, is formulated with the company's patented drug-delivery vehicle (DuraSite), designed to enhance the retention time of the antibiotic on the surface of the eye.

The approval follows completion of two phase III clinical trials conducted in more than 1,400 patients in the United States and Latin America. In these studies, the solution was administered twice daily on the first 2 days, then once daily on the third, fourth, and fifth days. Results demonstrated that the anti-infective solution provided clinically and statistically significant improvements in clinical resolution of symptoms and bacterial eradication compared with placebo. Also, the agent was found to be equivalent in clinical resolution and bacterial eradication when compared with tobramycin administered four times a day for 5 days.

Under the terms of a previously announced license agreement, Inspire Pharmaceuticals will commercialize the topical solution in the United States and Canada. The FDA approval triggered a $19 million payment from Inspire Pharmaceuticals to InSite Vision.

To gain exclusive marketing rights to the anti-infective, Inspire Pharmaceuticals initially paid InSite Vision $13 million. Inspire Pharmaceuticals also will pay a royalty-20% in the first 2 years of commercialization and 25% thereafter-on net sales of the antibiotic in the United States and Canada.

InSite Vision is pursuing additional commercial partnerships to market the solution in other geographic areas.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
© 2025 MJH Life Sciences

All rights reserved.